Incidence of antibodies to interferon-β in patients treated with recombinant human interferon-β1a from mammalian cells

Cytokines, Cellular and Molecular Therapy

Volumn 3, Issue 1, 1997, Pages 27-32

  Abdul Ahad, A K ^a   Galazka, A R ^a   Revel, M ^b   Biffoni, M ^a   Borden, E C ^c  

^a Serono International SA   (Switzerland)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Immunogenicity; Interferon 1a; Multiple sclerosis; NABs; Neutralizing antibodies

Indexed keywords

BETA1 INTERFERON; INTERFERON; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; BIOASSAY; CANCER; CHO CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MAMMAL CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INFECTION;

ANIMALS; ANTIBODY FORMATION; CHO CELLS; CLINICAL PROTOCOLS; CRICETINAE; CROSS REACTIONS; DOUBLE-BLIND METHOD; ESCHERICHIA COLI; FEMALE; HUMANS; INTERFERON-BETA; MALE; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS;

EID: 0030823454     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Colby CB, Inoue M, Thompson M et al, Immunologic differentiation between E. coli and CHO cell-derived recombinant and natural human β-interferons. J Immunol (1984) 133: 3091-5.
2. Dummer R, Muller W, Nestle F et al, Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer (1991) 67: 2300-4.
3. Fierlbeck G, Schreiner T, Schaber B et al, Neutralizing interferon β antibodies in melanoma patients treated with recombinant and natural interferon β. Cancer Immunol Immunother (1994) 39: 263-8.
4. Brand CM, Leadbeater L, Budmian R et al, Successful re-treatment of an interferon-resistant polycythaemia vera patient with lymphoblastoid interferon-αN1 and in vitro studies on the specificity of the antibodies. Br J Haematol (1994) 86: 216-18.
5. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group, Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology (1995) 45: 1277-85.
6. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group, Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology (1996) 47: 889-94.
7. Knobler RL, Greenstein JI, Johnson KP et al, Systemic recombinant human interferon-β treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res (1993) 13: 333-40.
8. Jacobs LD, Cookfair DL, Rudick RA et al, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol (1996) 39: 285-94.
9. Chernajovsky Y, Mory Y, Chen L, et al, Efficient constitutive production of human fibroblast Interferon by hamster cells transformed with the IFN-β1 gene fused to an SV40 early promoter. DNA (1984) 3: 297-308.
10. Kawade Y, Quantitation of neutralization of interferon by antibody. Meth Enzymol (1986) 119: 558-73.
11. Bonetti P, Diodati G, Drago C et al, Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-α. J Hepatol (1994) 20: 415-20.
12. Dore-Duffy P, Donaldson JO, Rothman BL et al, Antinuclear antibodies in multiple sclerosis. Arch Neurol (1982) 39: 504-6.
13. Kiessling WR, Pflughaupt KW, Antithyroid antibodies in multiple sclerosis. Lancet (1980) i: 41.
14. Valls C, Pavia C, Rivera F, Antigenicity of commercial growth hormone products. In: Growth Disorders: The State of the Art (ed I Cavallo, JC Job) 321-8. Raven Press, New York, 1991.
15. Valls C, Pavia C, Rivera F, Treatment with growth hormone. A comparative study of the antigenicity of different commercial preparations. In: Two Decades of Experience in Growth (ed M Pombo, RG Rosenfeld) 1-14. Raven Press, New York, 1991.
16. Spiegel RJ, Spicehandler JR, Jacobs SL et al, Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med (1986) 80: 223-8.
17. 2b in human recipients. J Interferon Res (1989) 9(Suppl 1): S33-6.
18. Antonelli G, Currenti M, Turriziani O et al, Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J Infect Dis (1991) 163: 882-5.
19. Von Wussow P, Freund M, Block B et al, Clinical significance of anti-IFN-α antibody titres during interferon therapy. Acta Derm Venereol (1987) 67: 635-6.
20. Freund M, Von Wussow P, Diedrich H et al, Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol (1989) 72: 350-6.
21. Von Wussow P, Jakschies D, Freund M et al, Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Brit J Haematol (1991) 78: 210-16.
22. Von Wussow P, Pralle H, Hochkeppel H-K et al, Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukemia. Blood (1991) 78: 38-43.
23. Lok ASF, Lai CL, Leung EKY, Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology (1990) 12: 1266-70.
24. Quesada JR, Rios A, Swanson D et al, Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol (1985) 3: 1522.
25. Quesada JR, Itri L, Gutterman J, Alpha interferons in hairy cell leukaemia (HCL). A five year follow up in 100 patients. J Interferon Res (1987) 7: 678.
26. Casato M, Lagana B, Antonelli G et al, Long-term results of therapy with interferon-α for type II essential mixed cryoglobulinemia. Blood (1991) 78: 3142-7.
27. Merup M, Tornebohm-Roche E, Engman K et al, Human leucocyte interferon-α therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-α2a. Eur J Cancer (1994) 30A: 1729-30.